All In Biotech

Drug Trial Radar · NCT01867164

A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis

A Prospective, Open-Label, Comparative, Parallel Double-Arm, Multicentric Clinical Study to Evaluate the Efficacy of an Ovule With Triple Active Agents (Terconazole, Clindamycin, Fluocinolone) Administered Once Per Day for Three Days Versus an Ovule With Triple Active Agents (Metronidazole, Nystatin, Fluocinolone) Administered Once Per Day for Ten Days to Treat Secondary Vulvar/Vaginal Symptoms of Vaginitis/Infectious Vaginosis (Bacterial and/or Mycotic and/or Parasitic)

Last checked: Nov 19, 2026Latest source record: Dec 24, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

160

Actual

Start

Dec 2007

Primary completion

Dec 2008

Study completion Dec 2008

Sponsor

Lead sponsor
Janssen-Cilag, S.A.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jun 3, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this comparative study is to evaluate the efficacy of an ovule with triple active agents (terconazole, clindamycin and fluocinolone) versus another ovule with triple active agents (nystatin, metronidazole and fluocinolone) in the treatment of symptoms caused by the presence of vaginitis (inflammation of the vagina) or bacterial vaginosis (polymicrobial, nonspecific vaginitis associated with positive cultures of Gardnerella vaginalis and other anaerobic organisms and a decrease in lactobacilli).

Conditions

  • Vaginitis
  • Infectious Vaginosis

Interventions

  • Gynoclin VDrug

    One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.

  • Vagitrol VDrug

    One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Presence or Absence of Symptoms 3 Days After TreatmentTime frame: 3 days after treatment (Day 7 for Gynoclin V or Day 13 for Vagitrol V)
  2. Percentage of Participants With Presence or Absence of Symptoms 8 Days After TreatmentTime frame: 8 days after treatment (Day 12 for Gynoclin V or Day 18 for Vagitrol V)
  3. Percentage of Participants With the Presence of Microorganisms (Single-celled, Tiny Organisms That Include Fungi, Bacteria, Viruses) 3 Days After TreatmentTime frame: 3 days after treatment (Day 7 for Gynoclin V or Day 13 for Vagitrol V)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Mexico City, Mexico

  • Site not named

    DF, Mexico City, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.